These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

Telitacicept is a dual inhibitor of both B-lymphocyte stimulator and a proliferation-inducing ligand, cytokines that promote B cell survival and production of pathogenic galactose-deficient IgA1.

The VISIONARY trial is testing sibeprenlimab, a humanized IgG2 monoclonal antibody, in patients with IgA nephropathy, a population at high risk for kidney failure.

H OUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients ...

The urinary albumin-creatinine ratio (UACR) is more strongly associated with kidney failure than the urinary ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein. A recent study that measured reductions in urinary protein in patients with a rare kidney ...

Inpatients with type 2 diabetes who consume larger quantities of sodium may have higher urinary protein levels without other markers of acute kidney injury, according to findings published in the ...

Foamy urine can be a sign of kidney trouble, but it is not always serious. Research shows only a third of people with foamy ...

The ESA will be testing a protein powder called Solein, which contains a compound found in urine, on a mission aboard the ISS ...